The Advisory Committee on Immunization Practices, the CDC panel that sets the federal vaccine schedule, met this week under an entirely reconstituted membership after Health and Human Services Secretary Robert F. Kennedy Jr. removed all 17 previous members in June and installed replacements, including five appointed just days before the meeting, according to PBS NewsHour. Kennedy has said publicly that a full replacement of the committee was necessary to rebuild public confidence in vaccine science, a rationale he laid out when he dismissed the prior panel.
At the meeting, the reshaped committee voted to narrow the national recommendation for the combination measles-mumps-rubella-varicella vaccine, advising that children under four receive separate MMR and varicella doses rather than the combined shot, according to KFF Health News. The panel also discussed delaying the first hepatitis B dose from birth to at least one month for most infants but ultimately tabled that vote after what KFF Health News described as a confused and unusual sequence of votes spanning Thursday evening into Friday morning.
Testimony raised questions about political pressure
Former CDC Director Susan Monarez told the Senate Health, Education, Labor and Pensions Committee that Kennedy asked her, before her removal, to commit in advance to approving every ACIP recommendation regardless of the underlying scientific evidence, and to dismiss career vaccine policy officials without cause, according to her testimony as reported by Reuters. Monarez said she was not consulted before the original 17 committee members were fired and learned of it through media reports. HHS has not disputed that Kennedy sought changes to the childhood schedule, framing the changes as a restoration of scientific rigour rather than political interference.
Scientific American reported that several new panel members have made statements questioning vaccine safety or opposing mandates, and that the meeting drew concern from former public health officials who argued the changes could reduce access to established childhood immunizations, according to Scientific American. The Guardian separately reported that public health researchers viewed the MMRV vote as a departure from decades of consensus favouring the combination shot for convenience and higher completion rates, according to The Guardian.
Two competing definitions of legitimacy
The core dispute is not really about a single vote on a single vaccine. It is about who gets to decide what counts as settled science, and whether the previous ACIP membership represented disinterested expertise or, as Kennedy has alleged, a captured process insulated from public accountability. Neither side disputes that the committee changed entirely. What they dispute is whether that change constitutes correction or capture by a different set of interests.
How the outlets framed it
Reuters and CNN have generally framed the ACIP overhaul as a politically driven erosion of scientific consensus, emphasizing Monarez’s testimony that Kennedy demanded blanket pre-approval of recommendations and dismissed officials without cause. Scientific American and The Guardian likewise stressed that new panel members have made unproven claims about vaccines, a framing that treats the prior committee’s expertise as the baseline against which the new panel should be judged. Conservative and independent commentary, by contrast, has treated the prior committee’s membership itself as the problem to be corrected, arguing that a body seen as reflexively aligned with pharmaceutical industry consensus needed replacing regardless of credentials. The difference between these framings turns less on the facts of what happened at the meeting, which are largely agreed upon, than on which committee, old or new, is assumed to have owned scientific legitimacy from the outset.
What is not in dispute is that the vaccine schedule millions of American families rely on is now set by a panel whose composition changed entirely within a matter of months, twice, and that the change was driven from the top by a single cabinet secretary’s stated conviction that the prior process had lost public trust. Whether the new panel restores that trust, or merely relocates the question of who controls it, is likely to remain unresolved heading into flu season.
